As shown in Figure 9C–E, although all classical markers of T2DM increased, both the metformin- and DhHP-6-treated groups led to a significant reduction in ALT, AST, and ALP compared to the model group, consistent with the results obtained from liver sections. The gene discussed is GPT; the disease is type 2 diabetes mellitus.